Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
30 September 2025 at 9.00 EEST

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 26 September 2025 below (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

% of shares and voting rights
(total of point A)% of shares and voting rights through financial instruments
(total of point B)Total of both in % (points A + B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reachedBelow 5% shares




Below 5% voting rightsBelow 5% shares




Below 5% voting rightsBelow 5% shares




Below 5% voting rights141,134,278 shares




747,062,917 voting rightsPosition of previous notification (if applicable)

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares
ISIN codeNumber of shares and voting rights% of shares and voting rights Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)FI0009014377 Below 5% shares




Below 5% voting rights Below 5% shares




Below 5% voting rights POINT A SUBTOTALBelow 5% shares




Below 5% voting rights Below 5% shares




Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rightsAmerican Depositary Receipt (US68628Y1047)N/AN/APhysicalBelow 5% shares




Below 5% voting rights Below 5% shares




Below 5% voting rights POINT B SUBTOTALBelow 5% shares




Below 5% voting rights Below 5% shares




Below 5% voting rights

Orion Corporation

Liisa Hurme

President and CEO Mikko Kemppainen

General Counsel

Contact person:
Tuukka Hirvonen, Head of Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.